Soliton completes human trials of its RAP Device.
Soliton completed the human trials of its proprietary Rapid Acoustic Pulse, or RAP, Device to support the Company's FDA 510 submission. The Company conducted three rounds of human trials to study the use of the RAP device to accelerate tattoo fading. "The human trials provided evidence of the potential for the RAP technology to accelerate tattoo fading," said the company. "The combination treatment of the RAP device and a laser outperformed a laser alone, showing an average of 80% fading after only two visits vs 44% fading for the laser alone. After 3 Soliton Multi-Pass treatments, 100% of the treated tattoos had a 'Complete' (76-100% faded) response; in comparison, only 17% of the tattoos treated with the Laser Only had a 'Complete' response."
|Printer friendly Cite/link Email Feedback|
|Article Type:||Concert review|
|Date:||Mar 19, 2019|
|Previous Article:||First Midwest announces approval of $180M stock repurchase program.|
|Next Article:||Kathleen Sebelius joins Exact Sciences Board of Directors.|